Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Allegra-D Generic Receives Final Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

A launch of the generic fexofenadine/pseudoephedrine combination would be "at risk" because of ongoing patent litigation with Sanofi-Aventis. Final ANDA approval follows resolution of a dispute between Barr and FDA over 180-day exclusivity for the product.

You may also be interested in...



Teva Launches Generic Allegra Tablets Despite Patent Litigation

Marketing agreement between Barr, which is waiving its exclusivity, and Teva would allow the companies to share the litigation hazard of the "at risk" launch.

Teva Launches Generic Allegra Tablets Despite Patent Litigation

Marketing agreement between Barr, which is waiving its exclusivity, and Teva would allow the companies to share the litigation hazard of the "at risk" launch.

Senate Health Members Take A Time-Out From Crawford Vote To Discuss Plan B

Committee Chair Enzi (R-Wyo.) postpones panel's vote on Crawford's nomination for FDA commissioner "to provide more time to address issues that have been raised on both sides of the aisle."

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel